JP2015506174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506174A5 JP2015506174A5 JP2014551569A JP2014551569A JP2015506174A5 JP 2015506174 A5 JP2015506174 A5 JP 2015506174A5 JP 2014551569 A JP2014551569 A JP 2014551569A JP 2014551569 A JP2014551569 A JP 2014551569A JP 2015506174 A5 JP2015506174 A5 JP 2015506174A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- acid molecule
- molecule according
- cgrp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 63
- 102000039446 nucleic acids Human genes 0.000 claims 63
- 239000002773 nucleotide Substances 0.000 claims 30
- 125000003729 nucleotide group Chemical group 0.000 claims 30
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 18
- 239000000523 sample Substances 0.000 claims 15
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 claims 11
- 208000002193 Pain Diseases 0.000 claims 8
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 239000002336 ribonucleotide Substances 0.000 claims 6
- 108091028664 Ribonucleotide Proteins 0.000 claims 5
- 239000005547 deoxyribonucleotide Substances 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 5
- 125000002652 ribonucleotide group Chemical group 0.000 claims 5
- 208000000094 Chronic Pain Diseases 0.000 claims 4
- 208000005298 acute pain Diseases 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 101001081479 Homo sapiens Islet amyloid polypeptide Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 230000036592 analgesia Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 229960005181 morphine Drugs 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- -1 polyoxypropylene Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2012/000089 | 2012-01-10 | ||
| PCT/EP2012/000089 WO2012095303A1 (en) | 2011-01-10 | 2012-01-10 | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
| EP12000105.2 | 2012-01-10 | ||
| EP12000105 | 2012-01-10 | ||
| PCT/EP2013/000055 WO2013104539A1 (en) | 2012-01-10 | 2013-01-10 | Nucleic acids specifically binding cgrp |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015506174A JP2015506174A (ja) | 2015-03-02 |
| JP2015506174A5 true JP2015506174A5 (enExample) | 2016-03-03 |
Family
ID=48781062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551569A Pending JP2015506174A (ja) | 2012-01-10 | 2013-01-10 | Ｃｇｒｐに特異的に結合する核酸 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9163243B2 (enExample) |
| EP (1) | EP2802659A1 (enExample) |
| JP (1) | JP2015506174A (enExample) |
| KR (1) | KR20140111704A (enExample) |
| CN (1) | CN104136612A (enExample) |
| AU (1) | AU2013209130A1 (enExample) |
| BR (1) | BR112014016939A2 (enExample) |
| CA (1) | CA2860809A1 (enExample) |
| HK (1) | HK1198370A1 (enExample) |
| IL (1) | IL233515A0 (enExample) |
| MX (1) | MX2014008456A (enExample) |
| RU (1) | RU2014132706A (enExample) |
| SG (1) | SG11201403769YA (enExample) |
| WO (1) | WO2013104539A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2802660T3 (pl) | 2012-01-10 | 2020-07-27 | Aptarion Biotech Ag | Nowe kwasy nukleinowe wiążące c5a |
| FI3119431T3 (fi) | 2014-03-21 | 2024-03-20 | Teva Pharmaceuticals Int Gmbh | Kalsitoniinigeeniin liittyvää peptidiä vastaan suunnattuja antagonisti-vasta-aineita ja menetelmiä niiden käyttämiseksi |
| JP6584868B2 (ja) * | 2015-02-25 | 2019-10-02 | 学校法人 関西大学 | ゲル素材及びその製造方法 |
| CN108473560A (zh) * | 2015-09-24 | 2018-08-31 | 泰瓦制药国际有限公司 | 预防、治疗和减轻(持续性)创伤后头痛 |
| ES2607639B1 (es) | 2015-09-30 | 2018-02-28 | Urquima, S.A | Sal de ácido maleico de un intermedio de silodosina |
| KR20190066607A (ko) | 2016-09-23 | 2019-06-13 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
| AU2019378732A1 (en) * | 2018-11-12 | 2021-05-27 | Aptarion Biotech Ag | CXCL8 binding nucleic acids |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US6682886B1 (en) | 1994-04-28 | 2004-01-27 | Gilead Sciences, Inc. | Bivalent binding molecules of 7 transmembrane G protein-coupled receptors |
| ATE265466T1 (de) | 1994-08-16 | 2004-05-15 | Human Genome Sciences Inc | Calcitoninrezeptor |
| WO1996038579A1 (en) | 1995-06-02 | 1996-12-05 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to growth factors |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| RU2180311C1 (ru) | 2001-07-05 | 2002-03-10 | Мешалкин Георгий Алексеевич | Защитная пробка |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| ATE469164T1 (de) | 2001-10-26 | 2010-06-15 | Noxxon Pharma Ag | Modifizierte l-nukleinsäure |
| ATE441706T1 (de) | 2002-02-20 | 2009-09-15 | Gen Hospital Corp | Konjugate mit biologisch abbaubarem polymer und verwendung dafür |
| AU2003239841A1 (en) * | 2002-05-06 | 2003-11-17 | Grunenthal Gmbh | Cgrp binding nucleic acids |
| RU2394041C2 (ru) | 2003-04-13 | 2010-07-10 | Энзон Фармасьютикалз, Инк. | Полимерные олигонуклеотидные пролекарства |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| EP1713509A2 (de) | 2004-02-09 | 2006-10-25 | Noxxon Pharma AG | Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden |
| CA2940803A1 (en) | 2004-03-23 | 2005-10-27 | Ascendis Pharma Gmbh | Prodrug linker |
| WO2006052790A2 (en) | 2004-11-05 | 2006-05-18 | The Children's Hospital Of Philadelphia | Biodegradable linkers for molecular therapies |
| CN101217967B (zh) * | 2005-05-04 | 2014-09-10 | 诺松制药股份公司 | 镜像异构体的新用途 |
| AU2007296054B2 (en) | 2006-09-15 | 2013-03-28 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| US20100062436A1 (en) | 2006-10-31 | 2010-03-11 | Noxxon Pharma Ag | Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule |
| EP2561079A1 (en) | 2010-04-21 | 2013-02-27 | Noxxon Pharma AG | Lipid binding nucleic acids |
| CA2824073A1 (en) * | 2011-01-10 | 2012-07-19 | Noxxon Pharma Ag | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
-
2013
- 2013-01-10 MX MX2014008456A patent/MX2014008456A/es unknown
- 2013-01-10 JP JP2014551569A patent/JP2015506174A/ja active Pending
- 2013-01-10 CA CA2860809A patent/CA2860809A1/en not_active Abandoned
- 2013-01-10 HK HK14111873.3A patent/HK1198370A1/xx unknown
- 2013-01-10 RU RU2014132706A patent/RU2014132706A/ru not_active Application Discontinuation
- 2013-01-10 SG SG11201403769YA patent/SG11201403769YA/en unknown
- 2013-01-10 AU AU2013209130A patent/AU2013209130A1/en not_active Abandoned
- 2013-01-10 BR BR112014016939A patent/BR112014016939A2/pt not_active IP Right Cessation
- 2013-01-10 US US14/371,210 patent/US9163243B2/en not_active Expired - Fee Related
- 2013-01-10 CN CN201380009019.6A patent/CN104136612A/zh active Pending
- 2013-01-10 KR KR1020147022328A patent/KR20140111704A/ko not_active Withdrawn
- 2013-01-10 EP EP13700455.2A patent/EP2802659A1/en not_active Withdrawn
- 2013-01-10 WO PCT/EP2013/000055 patent/WO2013104539A1/en not_active Ceased
-
2014
- 2014-07-03 IL IL233515A patent/IL233515A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506174A5 (enExample) | ||
| JP2015509705A5 (enExample) | ||
| JP2013524792A5 (enExample) | ||
| RU2014132706A (ru) | Нуклеиновые кислоты, специфически связывающие cgrp | |
| RU2014132708A (ru) | НОВЫЕ СВЯЗЫВАЮЩИЕ C5a НУКЛЕИНОВЫЕ КИСЛОТЫ | |
| Cunha-Neto et al. | Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy | |
| Lennartz et al. | Structure-guided identification of a family of dual receptor-binding PfEMP1 that is associated with cerebral malaria | |
| Englund et al. | Programmable multivalent display of receptor ligands using peptide nucleic acid nanoscaffolds | |
| March et al. | The genetics of asthma and allergic disorders | |
| Handl et al. | Synthesis and evaluation of bivalent NDP-α-MSH (7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R) | |
| Haskell-Luevano et al. | Biological and conformational examination of stereochemical modifications using the template melanotropin peptide, Ac-Nle-c [Asp-His-Phe-Arg-Trp-Ala-Lys]-NH2, on human melanocortin receptors | |
| JP2009543567A5 (enExample) | ||
| JP2014533098A5 (enExample) | ||
| Arttamangkul et al. | Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the “address” sequence | |
| CN109439664A (zh) | 结合il-6的适体及其在治疗或诊断il-6介导的疾患中的用途 | |
| RU2008136907A (ru) | Нуклеиновые кислоты, связывающиеся с мср-1 | |
| JP2020533413A (ja) | ベータ−カテニンの機能を調節する薬剤及びその方法 | |
| Zhang et al. | NMR and modeling studies of a synthetic extracellular loop II of the κ opioid receptor in a DPC micelle | |
| Todorov et al. | Synthesis, characterization and nociceptive screening of new VV-hemorphin-5 analogues | |
| Li et al. | Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin? | |
| Kokko et al. | In vitro analysis of stable, receptor-selective neurotensin [8− 13] analogues | |
| Deuis et al. | Activation of κ opioid receptors in cutaneous nerve endings by conorphin-1, a novel subtype-selective conopeptide, does not mediate peripheral analgesia | |
| JP6041373B2 (ja) | ＴＮＦ−αに結合するアプタマー分子 | |
| EP4317456B1 (en) | Piezo type mechanosensitive ion channel component 1 (piezo1) variants and uses thereof | |
| Vaszar et al. | Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats |